Predictors of delayed culture conversion among Ugandan patients
Open Access
- 24 April 2017
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-8
Abstract
Estimates of month-2 culture conversion, a proxy indicator of tuberculosis (TB) treatment efficacy in phase-2 trials can vary by culture-type and geographically with lower rates reported among African sites. The sub-study aimed at comparing TB detection rates of different culture media, within and across rifampicin-based regimens (R10, 15 and 20 mg/Kg) over a 6-month treatment follow-up period, and to establish predictors of month-2 culture non-conversion among HIV-negative TB patients enrolled at RIFATOX trial site in Uganda. Unlike in other Rifatox Trial sites, it is only in Uganda were Lowenstein-Jensen (LJ) and Mycobacteria growth indicator tube (MGIT) were used throughout 6-months for treatment monitoring. Conversion rates were compared at month-2, 4 and 6 across cultures and treatment-type. Binomial regression analysis performed for predictors of month-2 non-conversion. Of the 100 enrolled patients, 45% had converted based on combined LJ and MGIT by month-2, with no significant differences across treatment arms, p = 0.721. LJ exhibited higher conversion rates than MGIT at month-2 (58.4% vs 56.0%, p = 0.0707) and month-4 (98.9% vs 88.4%, p = 0.0391) respectively, more so within the high-dose rifampicin arms. All patients had converted by month-6. Time-to-TB detection (TTD) on MGIT and social service jobs independently predict month-2 non-conversion. The month-2 culture conversion used in phase 2 clinical trials as surrogate marker of treatment efficacy is influenced by the culture method used for monitoring mycobacterial response to TB treatment. Therefore, multi-centric TB therapeutic trials using early efficacy endpoint should use the same culture method across sites. The Time-to-detection of MTB on MGIT prior to treatment and working in Social service jobs bear an increased risk of culture non-conversion at month-2. ISRCTN ISRCTN55670677 . Registered 09th November 2010. Retrospectively registered.Keywords
This publication has 26 references indexed in Scilit:
- An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and RelapsePLOS ONE, 2013
- Incubation Time of Mycobacterial Cultures: How Long Is Long Enough To Issue a Final Negative Report to the Clinician?Journal of Clinical Microbiology, 2012
- Baseline Predictors of Sputum Culture Conversion in Pulmonary Tuberculosis: Importance of Cavities, Smoking, Time to Detection and W-Beijing GenotypePLOS ONE, 2012
- Geographic Differences in Time to Culture Conversion in Liquid Media: Tuberculosis Trials Consortium Study 28. Culture Conversion Is Delayed in AfricaPLOS ONE, 2011
- Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin ConcentrationsAntimicrobial Agents and Chemotherapy, 2010
- Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysisThe Lancet Infectious Diseases, 2010
- Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activityTuberculosis, 2010
- Evaluation of Direct Detection of Mycobacterium tuberculosis Rifampin Resistance by a Nitrate Reductase Assay Applied to Sputum Samples in Cotonou, BeninJournal of Clinical Microbiology, 2007
- Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosisInternational Journal Of Clinical Practice, 2006
- Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006